Anti-Human CD21 (Clone Bu32) – APC

Myeloma cell line Rob

This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Red Laser (650 nm)

IHC,
FC

Bu32 activity is directed against human CD21.

CD21 (complement receptor type 2; CR2) is a type I membrane glycoprotein that functions as the receptor for complement C3 fragments iC3b, C3dg and C3d, low-affinity IgE receptor CD23, type I cytokine, interferon-alpha as well as the Epstein-Barr virus gp350/220 envelope protein ^{1, 2, 3} CD21 is part of a molecular complex that includes CD19, Leu 13 and TAPA-1 ¹ . CD21 enhances B cell proliferation and modulates the immune response ¹ . By binding to C3d, CD21 links the innate complement-mediated immune response against pathogens and foreign antigens to the adaptive immune response ³ . Additionally, the CD19/CD21 complex functions synergistically with the B cell Ag receptor (BCR) to reduce the threshold for B cell activation. CD21 is also required for the extracellular trapping of HIV by lymph node cells, and disruption of this process reduces HIV reservoirs ⁴ . Furthermore, CD21 affects the ability of CD19-CAR-T cells to recognize malignant B cells that are CD19-positive and impairs its antitumor function ⁵ .

Bu32 was produced in mouse at the University of Birmingham, England, and was shown to be specific to CD21 antigen via tests on cell lines, histological tissue sections, and blood cells ^{6, 7, 8, 9} . Bu32 was authenticated in the IVth and Vth International Leukocyte Workshops ⁹ .

CD21 is expressed on the surface of B lymphocytes, a subpopulation of peripheral blood T lymphocytes and thymocytes, follicular dendritic cells, some epithelial cells, fetal astrocytes, and chronic lymphocytic leukemia cells. CD21 is also released in soluble form in human serum as well as by human B and T lymphocytic cell lines.

C3d, EBV

P20023

1 Frémeaux-Bacchi V, Bernard I, Maillet F, et al. Eur J Immunol. 26(7):1497-1503. 1996.
2 https://www.uniprot.org/uniprotkb/P20023/entry
3 Hannan JP. Curr Protein Pept Sci. 17(5):463-487. 2016.
4 Ho J, Moir S, Kulik L, et al. J Immunol. 178(11):6968-6974. 2007.
5 Li D, Xu Q, Hu Y, et al. J Leukoc Biol. 112(4):913-918. 2022.
6 Ling N, Hansel T, Richardson P, et al. Clin Exp Immunol. 84(1):16-22. 1991.
7 Ling NR, Brown B, Hardie D. J Immunol Methods. 173(1):11-17. 1994.
8 Ling NR, Brown B, Hardie D. Clin Exp Immunol. 101(2):369-375. 1995.
9 Ling NR, Hardie DL, Johnson GD, et al. Clin Exp Immunol. 113(3):360-366. 1998.
10 Maeda K, Matsuda M, Suzuki H, et al. J Histochem Cytochem. 50(11):1475-1486. 2002.
11 Wang C, Hillsamer P, Kim CH. BMC Immunol. 12:53. 2011.
12 Jackson HM, Foley KE, O'Rourke R, et al. BMC Genet. 21(1):101. 2020.
13 Herishanu Y, Kay S, Dezorella N, et al. J Immunol. 190(2):784-793. 2013.
14 Björck P, Elenström-Magnusson C, Rosén A, et al. Eur J Immunol. 23(8):1771-1775. 1993.